Antiandrogen treatments in locally advanced prostate cancer: are they all the same? (Q34548160)

2 August 2017

1 reference

title

Antiandrogen treatments in locally advanced prostate cancer: are they all the same? (English)

1 reference

2 August 2017

1 reference

David Gillatt

1

1 reference

2 August 2017

publication date

1 August 2006

1 reference

Journal of Cancer Research and Clinical Oncology

2 August 2017

published in

1 reference

2 August 2017

volume

132 Suppl 1

1 reference

2 August 2017

page(s)

S17-26

1 reference

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

2 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00432-006-0133-5

Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00432-006-0133-5

Side effects of androgen deprivation therapy: monitoring and minimizing toxicity

21 January 2018

1 reference

12 December 2020

Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole

1 reference

12 December 2020

Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer

1 reference

12 December 2020

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

12 December 2020

The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society

1 reference

12 December 2020

Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy

1 reference

12 December 2020

Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial

1 reference

12 December 2020

Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma

1 reference

12 December 2020

Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer

1 reference

12 December 2020

Progressive osteoporosis during androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project

1 reference

12 December 2020

Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol

1 reference

12 December 2020

Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group

1 reference

12 December 2020

Cancer control with radical prostatectomy alone in 1,000 consecutive patients

1 reference

12 December 2020

Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.

1 reference

12 December 2020

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

12 December 2020

Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.

1 reference

12 December 2020

Cancer statistics, 2006

1 reference

12 December 2020

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis

1 reference

12 December 2020

Endocrine profiles during administration of the new non‐steroidal anti‐androgen Casodex in prostate cancer

1 reference

12 December 2020

Cancer incidence and mortality in Europe, 2004

1 reference

12 December 2020

Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup

1 reference

12 December 2020

Nilutamide: an antiandrogen for the treatment of prostate cancer

1 reference

12 December 2020

Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition

1 reference

12 December 2020

A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma

1 reference

12 December 2020

Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study

1 reference

12 December 2020

Radical prostatectomy versus watchful waiting in early prostate cancer

1 reference

12 December 2020

Effects of cyproterone acetate and a long-acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate.

1 reference

12 December 2020

Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.

1 reference

12 December 2020

Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cance

1 reference

12 December 2020

Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer

1 reference

12 December 2020

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

12 December 2020

Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy

1 reference

12 December 2020

Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy

1 reference

12 December 2020

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years

1 reference

12 December 2020

Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer

1 reference

12 December 2020

Treatment options for early prostate cancer

1 reference

12 December 2020

Endocrine effects of cyproterone acetate in patients with prostatic cancer

1 reference

12 December 2020

A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No.

1 reference

12 December 2020

The role of antiandrogen monotherapy in the treatment of prostate cancer

1 reference

12 December 2020

Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer

1 reference

12 December 2020

Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function

1 reference

12 December 2020

Treatment of hot flushes in breast and prostate cancer

1 reference

12 December 2020

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

1 reference

12 December 2020

Lipoprotein levels following treatment with cyproterone acetate or LHRH analogues.

1 reference

12 December 2020

10.1007/S00432-006-0133-5

Identifiers

DOI

1 reference

2 August 2017

1 reference